Hints and tips:
Related Special Reports
...” versus US and European peers....
...AstraZeneca makes 40 per cent of its sales in the US, like many European pharmaceutical companies, and it has sought to justify the increases by comparing Soriot’s pay with US pharma bosses....
...AstraZeneca has a market capitalisation of £171bn....
...Flumist is recommended in the US. This article has been corrected to remove an erroneous statement to the contrary....
...AstraZeneca, the second most valuable company on the FTSE, won investors’ approval on Thursday for a pay rise of up to £1.8mn for its chief executive Pascal Soriot....
...Europe is “falling behind” the US and China in life sciences innovation, the chief executive of AstraZeneca has said, warning that one of the continent’s leading industries needs to spend more on research...
...The writer is chair of AstraZeneca The AGM season is in full swing, and with it comes the usual set of controversies around remuneration....
...AstraZeneca has also sought to justify the changes by saying it is competing with US rivals. Like many European pharmaceutical companies, it makes a large proportion of sales in the US....
...Soriot set the goal to reach $45bn in sales by 2023 a decade ago, as part of its campaign to see off a £69.4bn hostile pursuit from US rival Pfizer. Back then AstraZeneca’s revenues were $26bn....
...Shares in AstraZeneca dipped 1.1 per cent in morning trading....
...AstraZeneca also announced on Monday that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free...
...He was the technical lead in chemical development for Truqap, which was approved by the US’s Food and Drug Administration in November to treat some forms of breast cancer....
...by other sectors because of its geopolitical rift with the US....
...London-listed shares in the drugmaker rose by 1.4 per cent in morning trading on Tuesday, while Icosavax surged 45 per cent before the US open....
...European stocks fell on Thursday, dragged down by a global sell-off in the technology sector and signs of sticky inflation in the US....
...AstraZeneca has signed a deal worth up to $247mn with Absci Corporation of the US to design an antibody to fight cancer, the latest tie-up in fast-expanding efforts to use artificial intelligence for drug...
...Shares in Daiichi soared 14 per cent on Friday after the deal was announced, while Merck, known as MSD outside the US, gained 1.6 per cent....
...AstraZeneca has settled disputes on drugs Nexium and Prilosec for a combined total of $425mn, “effectively” resolving product liability claims in some US states....
...Wegovy’s official list price in the UK is about £175.80 per pack of 2.4mg doses — about a sixth of the US list price, though health systems and insurers, including the NHS, negotiate confidential discounts...
...AstraZeneca has settled disputes on stomach drugs Nexium and Prilosec for a combined total of $425mn, “effectively” resolving product liability claims in some US states....
...AstraZeneca shareholders this month approved a bumper pay rise for chief executive Pascal Soriot to £18.7mn, justifying the move by saying the company’s main rivals are US-based....
...London Stock Exchange Group and Smith & Nephew are among the FTSE 100 companies hoping to follow AstraZeneca by pushing through pay increases for their executives at upcoming annual meetings....
...AstraZeneca chief executive Pascal Soriot said last month that the company planned to build independent drug supply chains for the US and China....
...AstraZeneca: Shares rose 3.4 per cent after its drug Tagrisso was approved in the US to be used alongside chemotherapy for lung cancer patients....
...AstraZeneca has become the latest large pharmaceutical company to sue the US over a law that allows the government to negotiate some drug prices for the first time....
International Edition